Bimekizumab, a humanized monoclonal anti-IL17A/F antibody has recently been investigated in a phase III study in HS patients and showed rapid responses to therapy as well as significant improvements in patient-reported outcomes such as quality of life [11]. The gene discussed is IL17A; the disease is histiocytic sarcoma.